

### Daftar Pustaka

- Aikens, J. E., Trivedi, R., Heapy, A., Pfeiffer, P. N., & Piette, J. D. (2015). Potential Impact of Incorporating a Patient-Selected Support Person into mHealth for Depression. *Journal of General Internal Medicine*, 30(6), 797–803. <https://doi.org/10.1007/s11606-015-3208-7>
- Al-saadoon, M. (2015). *Adverse Effects of Medicines*. 15(May), 149–151. [https://doi.org/10.1016/S0140-6736\(00\)02799-9](https://doi.org/10.1016/S0140-6736(00)02799-9).World
- Alwi, I. (2015). Kriteria Empirik dalam Menentukan Ukuran Sampel Pada Pengujian Hipotesis Statistika dan Analisis Butir. *Formatif: Jurnal Ilmiah Pendidikan MIPA*, 2(2), 140–148. <https://doi.org/10.30998/formatif.v2i2.95>
- Byerly, M. J., Nakonezny, P. A., & Lescouflair, E. (2007). Antipsychotic Medication Adherence in Schizophrenia. *Psychiatric Clinics of North America*, 30(3), 437–452. <https://doi.org/10.1016/j.psc.2007.04.002>
- Castle, D., & Tran, N. (2009). Psychiatric Medication Information. *St. Vincent's Hospital Melbourne*.
- Chaula, A., Malawati, & Mamfaluti, T. (2017). *Perbandingan Antara Penggunaan Antipsikotik Atipikal Terhadap Peningkatan Kadar Gula Darah Sewaktu Pada Pasien Skizofrenia di BLUD RSJ Aceh Comparison Between Atypical Antipsychotics to Increase Direct Glucose Blood Level In Patients with Schizophrenia In*. 2, 1–5.
- Claudia, R. O., Rahmawati, D., & Fadraersada, J. (2018). Gambaran Karakteristik, Pola Pengobatan dan Kepatuhan Pasien HIV/AIDS Di Kota Samarinda. *Proceeding of Mulawarman Pharmaceuticals Conferences*, 8(November), 104–110.

<https://doi.org/10.25026/mpc.v8i1.311>

Dahlan, M. S. (2014). *Statistik untuk Kedokteran dan Kesehatan* (6th ed.). Jakarta: Epidemiologi Indonesia.

Dania, H., Faridah, I. N., Rahmah, K. F., Abdulah, R., Barliana, M. I., & Perwitasari, D. A. (2019). Hubungan Pemberian Terapi Antipsikotik terhadap Kejadian Efek Samping Sindrom Ekstrapiramidal pada Pasien Rawat Jalan di Salah Satu Rumah Sakit di Bantul, Yogyakarta. *Indonesian Journal of Clinical Pharmacy*, 8(1).  
<https://doi.org/10.15416/ijcp.2019.8.1.19>

DiBonaventura, M., Gabriel, S., Dupclay, L., Gupta, S., & Kim, E. (2012). A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia. *BMC Psychiatry*, 12. <https://doi.org/10.1186/1471-244X-12-20>

Edi, I. G. M. S. (2014). *Faktor-faktor yang mempengaruhi kepatuhan pasien pada pengobatan*. 1(1), 1–8.

Eticha, T., Teklu, A., Ali, D., Solomon, G., & Alemayehu, A. (2015). Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia. *PLoS ONE*, 10(3), 1–11.  
<https://doi.org/10.1371/journal.pone.0120560>

Fadilla, A. R., & Puspitasari, R. M. (2016). *Evaluasi Ketepatan Penggunaan Antipsikotik Pada Pasien Skizofrenia Rawat Inap*. 41–46.

Fialko, L., Garety, P. A., Kuipers, E., Dunn, G., Bebbington, P. E., Fowler, D., & Freeman, D. (2008). A large-scale validation study of the Medication Adherence Rating Scale (MARS). *Schizophrenia Research*, 100(1–3), 53–59.

<https://doi.org/10.1016/j.schres.2007.10.029>

Gebeyehu, D. A., Mulat, H., Bekana, L., Asemamaw, N. T., Birarra, M. K., Takele, W.

W., & Angaw, D. A. (2019). Psychotropic medication non-adherence among patients with severe mental disorder attending at Bahir Dar Felege Hiwote Referral hospital, north west Ethiopia, 2017. *BMC Research Notes*, 12(1), 2–7.

<https://doi.org/10.1186/s13104-019-4126-2>

Haddad, P., Brain, C., & Scott, J. (2014). *Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures*.

Handayani, D. S., Cahaya, N., & Srikartika, V. M. (2017). Pengaruh Pemberian Kombinasi Antipsikotik Terhadap Efek Samping Sindrom Ekstrapiramidal Pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum. *Farmaka*, 15(3), 86–95.

Handayani, L., Febriani, Rahmadanni, A., & Saufi, A. (2017). Faktor Risiko Kejadian Skizofrenia Di Rumah Sakit Jiwa Grhasia Daerah Istimewa Yogyakarta (Diy). *Humanitas*, 13(2), 135. <https://doi.org/10.26555/humanitas.v13i2.6069>

Hawari, D. (2012). *Skizofrenia Edisi Ketiga Pendekatan Holistik (BPSS) Bio-Psiko-Sosial*. Jakarta: Badan Penerbit Fakultas Kedokteran UI.

Higashi, K., Medic, G., Littlewood, K., Diez, T., Granstrom, O., & Hert, M. (2013). *Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence a systematic literature review. Therapeutic Advances in Psychopharmacology*.

Jarut, Y. M., Fatimawali, & Wiyono, W. I. (2013). Tinjauan Penggunaan Antipsikotik Pada Pengobatan Skizofrenia Di Rumah Sakit Prof . Dr . V . L. Ratumbuang

- Manado Periode Januari 2013- Maret 2013. *Jurnal Ilmiah Farmasi*, 2(03), 54–57.
- Jeon, S. W., & Kim, Y. (2017). *Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia : Antipsychotic Polypharmacy and Metabolic Syndrome*. <https://doi.org/10.3390/ijms18102174>
- Julaeha, Dwi Ananda, V. N., & Adhi Pradana, D. (2016). Gambaran Efek Samping Antipsikotik Pada Pasien Skizofrenia Pada Bangsal Rawat Inap Di Rs. Grhasia Yogyakarta Description of Side Effects of Anti Psychotic Drug in Schizophrenia Patient in Grhasia Hospital. *Farmasains*, 3(1), 35–41.
- Kane, J. M., Kishimoto, T., & Correll, C. U. (2013). Non-adherence to medication in patients with psychotic disorders: Epidemiology, contributing factors and management strategies. *World Psychiatry*, 12(3), 216–226. <https://doi.org/10.1002/wps.20060>
- Kaplan H.I, B. J. S. (1998). *Ilmu kedokteran Jiwa Darurat. cetakan I* (1st ed.). Jakarta: Penerbit Elex Media Komputer.
- Kembuan, M. A. H. N. (2016). Sidroma neuroleptik maligna patofisiologi, diagnosis, dan terapi. *Jurnal Biomedik (Jbm)*, 8(2). <https://doi.org/10.35790/jbm.8.2.2016.12675>
- Kemenkes RI. (2015). No Title بررسی ارتباط شیوه زندگی وابتلا به استئوآرتریت در زنان ومردان. *سالمند*. 53), 4(1, □□□□□ □ □□.
- Kemenkes RI. (2017). *Peraturan Kementrian Kesehatan Republik Indonesia Nomor 54 tahun 2017*.
- Kemenkes RI. (2018). *Hasil Utama Riskesdas 2018*.
- Kementrian Kesehatan Republik Indonesia. (2017). *Pedoman dan Standar Etik*

*Penelitian dan Pengembangan Kesehatan Nasional- Komisi Etik Penelitian dan Pengembangan Kesehatan Nasional Kementerian Kesehatan Republik Indonesia.*

Lestari, D. M. (2019). *Analisis Hubungan Faktor Kepatuhan Minum Obat Dengan Tingkat Kekambuhan (Relapse) pada Pasien Rawat Jalan Skizofrenia di rumah Sakit Khusus Hayunanto Medical Center Malang Periode 2016 dan 2017.*  
<https://doi.org/10.22201/fq.18708404e.2004.3.66178>

Llorca, P. M. (2008). Partial compliance in schizophrenia and the impact on patient outcomes. *Psychiatry Research*, 161(2), 235–247.  
<https://doi.org/10.1016/j.psychres.2007.07.012>

Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Pace, C. Di, ... Policlinico, O. M. (2014). *Review article : Clinical Pharmacology of Atypical Antipsychotics : an Update.* 1163–1191.

Maylani, R. Y., Fadraersada, J., & Ramadhan, A. M. (2018). *Studi Pemberian Antipsikotik terhadap Beberapa Jenis Skizofrenia di RSJD Atma Husada Mahakam Samarinda.* (November), 20–21.

McCabe, R., Bullenkamp, J., Hansson, L., Lauber, C., Martinez-Leal, R., Rössler, W., ... Priebe, S. (2012). The therapeutic relationship and adherence to antipsychotic medication in schizophrenia. *PLoS ONE*, 7(4).  
<https://doi.org/10.1371/journal.pone.0036080>

Mccallum, L., Lip, S., & Padmanabhan, S. (2014). Pharmacodynamic Pharmacogenomics. In *Handbook of Pharmacogenomics and Stratified Medicine.*  
<https://doi.org/10.1016/B978-0-12-386882-4.00018-9>

Mccann, T. V, Clark, E., & Lu, S. (2009). *Subjective side effects of antipsychotics and*

*medication adherence in people with schizophrenia.*

<https://doi.org/10.1111/j.1365-2648.2008.04906.x>

Noordraven, E. L., Wierdsma, A. I., Blanken, P., Bloemendaal, A. F. T., & Mulder, C.

L. (2016). Depot-medication compliance for patients with psychotic disorders:

The importance of illness insight and treatment motivation. *Neuropsychiatric*

*Disease and Treatment*, 12, 269–274. <https://doi.org/10.2147/NDT.S97883>

Nurjannah, I., Nurmasari, P., T Nugraha, I., Y Katan, D., & Hariyadi, K. (2017).

Interrater reliability of Client Categorization System as psychiatric status rating

scale in measuring psychiatric patients' health status. *International Journal of*

*Research in Medical Science*.

O'Connor, A., Ladebue, A., Peterson, J., Davis, R., Jung Grant, S., McCreight, M., &

Lambert-Kerzner, A. (2019). Creating and testing regulatory focus messages to

enhance medication adherence. *Chronic Illness*, 15(2), 124–137.

<https://doi.org/10.1177/1742395317753882>

Ourworldindata. (2017). No Title. Retrieved from Mental Health - Our World in Data.

(n.d.).

Palinkas, L. A., Horwitz, S. M., Green, C. A., Wisdom, J. P., Duan, N., Hoagwood,

K., ... Northwest, K. P. (2016). *Purposeful sampling for qualitative data*

*collection and analysis in mixed method implementation research*. 42(5), 533–

544. <https://doi.org/10.1007/s10488-013-0528-y>. Purposeful

Patel, K. R., Cherian, J., & Gohil, K. (2014). *Schizophrenia : Overview and Treatment*

*Options*. 39(9), 638–645.

Paterson, M., Kinnear, M., Bond, C., & McKinstry, B. (2017). A systematic review of

- electronic multi-compartment medication devices with reminder systems for improving adherence to self-administered medications. *International Journal of Pharmacy Practice*, 25(3), 185–194. <https://doi.org/10.1111/ijpp.12242>
- Pauly, A., Wolf, C., Mayr, A., Lenz, B., Kornhuber, J., & Friedland, K. (2015). Effect of a multi-dimensional and inter-sectoral intervention on the adherence of psychiatric patients. *PLoS ONE*, 10(10), 1–17. <https://doi.org/10.1371/journal.pone.0139302>
- Phan, S. V. (2016). Medication adherence in patients with schizophrenia. *International Journal of Psychiatry in Medicine*, 51(2), 211–219. <https://doi.org/10.1177/0091217416636601>
- Putri, D. E., & Fernandes, F. (2020). Analisis Faktor-Faktor Yang Berhubungan Dengan Relapse Pada Skizoprenia. *Ners.Fkep.Unand.Ac.Id*, 16(2), 38–44. Retrieved from <http://ners.fkep.unand.ac.id/index.php/ners/article/view/296>
- Ramdini, D. A., Sumiwi, S. A., Barliana, M. I., Destiani, D. P., & Nur, I. L. (2018). *Potensi Interaksi Obat pada Pasien Skizofrenia di Salah Satu Rumah Sakit Jiwa di Provinsi Jawa Barat Potential Drug Interactions on Schizophrenic Patients at a Mental Hospital in West Java , Indonesia*. 7(4). <https://doi.org/10.15416/ijcp.2018.7.4.280>
- Rantanen, P., Parkkari, T., Leikola, S., Airaksinen, M., & Lyles, A. (2017). An In-home Advanced Robotic System to Manage Elderly Home-care Patients' Medications: A Pilot Safety and Usability Study. *Clinical Therapeutics*, 39(5), 1054–1061. <https://doi.org/10.1016/j.clinthera.2017.03.020>
- Rootes-Murdy, K., Glazer, K. L., Van Wert, M. J., Mondimore, F. M., & Zandi, P. P.

- (2018). Mobile technology for medication adherence in people with mood disorders: A systematic review. *Journal of Affective Disorders*, 227(June 2017), 613–617. <https://doi.org/10.1016/j.jad.2017.11.022>
- Sari, M. M., & Rivandi, D. (2014). Hubungan Kepatuhan Minum Obat dan Dukungan Keluarga Terhadap Relaps Pada Pasien Skizofrenia. *Jurnal Medika Malahayati*, 1(2), 59–65.
- Satiti, R. N., W., S., & W., R. T. (2012). Hubungan Kualitas Hidup dengan Kepatuhan Pengobatan pada Pasien Skizofrenia di Rumah Sakit Grhasia Yogyakarta. *The Indonesian Journal of Health Science*, 2.
- Setyaningsih, T., Fitria, D., & Supriyanah. (2018). *Hubungan Faktir-faktor yang Memengaruhi Kepatuhan Minum Obat dengan Kepatuhan Pasien Skizofrenia yang Mengalami Halusinasi di RS Husada*. 2, 13–29.
- Siddiqui, M., Pattojoshi, A., & Khess, C. (2016). Factors affecting adherence in patients with schizophrenia. *International Journal of Advances in Medicine*, 3(1), 25–32. <https://doi.org/10.18203/2349-3933.ijam20151483>
- Sie, B. M. (2011). *Schizophrenia clinical features and diagnosis*. 3(February), 41–44.
- Simanjuntak, J. (2008). *Konseling Gangguan Jiwa & Okultisme*.
- Singh, N., & Varshney, U. (2019). Medication adherence: A method for designing context-aware reminders. *International Journal of Medical Informatics*, 132(May). <https://doi.org/10.1016/j.ijmedinf.2019.103980>
- Siregar, S., & Nuralita, N. S. (2018). *Gambaran Tingkat Kepatuhan Minum Obat Berdasarkan Faktor Demografi pada Pasien Rawat Jalan Skizofrenia di rumah Sakit Jiwa Prof. Dr. M. Ildrem Medan*. 2(2), 159–165.



- Stomski, N. J., Morrison, P., & Meyer, A. (2016). Antipsychotic medication side effect assessment tools: A systematic review. *Australian and New Zealand Journal of Psychiatry*, 50(5), 399–409. <https://doi.org/10.1177/0004867415608244>
- Stroup, T. S., & Gray, N. (2018). Management of common adverse effects of antipsychotic medications. *World Psychiatry*, 17(3), 341–356. <https://doi.org/10.1002/wps.20567>
- Subramaniam, S., Putu, N., Sasmita, S., Bagus, C., & Lesmana, J. (2018). Prevalensi Efek Samping Farmakoterapi Terhadap Penderita Skizofrenia di Rumah Sakit Jiwa Bangli, Propinsi Bali. *E-Jurnal Medika Udayana*, 7(1), 22–27.
- Susilawati, S., & Syafiq, M. (2015). Gambaran Tekanan (Stressor) yang Dihadapi Pasien Skizofrenia Rawat Jalan dan Strategi Coping. *Psikologi Teori & Terapan*, 5(2), 70–80.
- The National Institute of Mental Health. (2016a). Retrieved March 2, 2020, from <https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml>
- The National Institute of Mental Health. (2016b). Retrieved December 31, 2019, from <https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml>
- Triastuti, N., Irawati, D. N., Levani, Y., & Lestari, R. D. (2020). Faktor yang Mempengaruhi Tingkat Kepatuhan Konsumsi Obat Antidiabetes Oral pada Pasien Diabetes Melitus Tipe 2 di RSUD Kabupaten Jombang. *Medica Arteriana (Med-Art)*, 2(1), 27. <https://doi.org/10.26714/medart.2.1.2020.27-37>
- Üçok, A., & Gaebel, W. (2008). Side effects of atypical antipsychotics: A brief overview. *World Psychiatry*, 7(1), 58–62. <https://doi.org/10.1002/j.2051-5545.2008.tb00154.x>

- Ucok, A., Karadayi, G., Emiroglu, B., & Sartorius, N. (2013). Anticipated discrimination is related to symptom severity, functionality and quality of life schizofrenia. *Psychiatry Research*. <https://doi.org/10.1016/j.psychres.2013.02.022>.
- Waddell, L., & Taylor, M. (2008). *A new self-rating scale for detecting atypical or second-generation antipsychotic side effects*.
- Wahyudi, A., & Fibriana, A. I. (2016). Faktor Resiko Terjadinya Skizofrenia (Studi Kasus di Wilayah Kerja Puskesmas Pati II). *Public Health Perspective Journal*, 1(1), 1–12.
- Wardani, I. Y., & Dewi, F. A. (2018). Kualitas Hidup Pasien Skizofrenia Dipersepsikan Melalui Stigma Diri. *Jurnal Keperawatan Indonesia*, 21(1), 17–26. <https://doi.org/10.7454/jki.v21i1.485>
- Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (2010). Pharmacotherapy Handbook. In *AIAA Guidance, Navigation, and Control Conference*. <https://doi.org/10.2514/6.2010-8193>
- Wulandari, D. (2015). Analisis Faktor-Faktor yang Berhubungan dengan Kepatuhan Pasien Tuberkulosis Paru Tahap Lanjutan Untuk Minum Obat di RS Rumah Sehat Terpadu Tahun 2015. *Jurnal Administrasi Rumah Sakit*, 2(1), 17–28.
- Yeni, F., Husna, M., & Dachriyanus. (2016). *Dukungan Keluarga Memengaruhi Kepatuhan Pasien Hipertensi*. 19(3), 137–144.
- Yulianty, M. D., Cahaya, N., & Srikartika, V. M. (2017). *Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan*. 3(May), 153–164.

- Zahnia, S., & Wulan Sumekar, D. (2016). Kajian Epidemiologis Skizofrenia. *Majority*, 5(5), 160–166. Retrieved from <http://joke.kedokteran.unila.ac.id/index.php/majority/article/view/904/812>
- Zygmunt, A., Ph, D., Olfson, M., Boyer, C. a, & Mechanic, D. (2002). Reviews and Overviews in Schizophrenia. *American Journal of Psychiatry*, 159(7), 1653–1664.